List of Excipients in Branded Drug DOXYCYCLATE HYCLATE

« Back to Dashboard

Generic Drugs Containing DOXYCYCLATE HYCLATE

Company	Ingredient	NDC	Excipient
Liberty Pharmaceuticals Inc	doxycycline hyclate	0440-1481	ALCOHOL
Liberty Pharmaceuticals Inc	doxycycline hyclate	0440-1481	BUTYL ALCOHOL
Liberty Pharmaceuticals Inc	doxycycline hyclate	0440-1481	CELLULOSE, MICROCRYSTALLINE
Liberty Pharmaceuticals Inc	doxycycline hyclate	0440-1481	FD&C BLUE NO. 1
Liberty Pharmaceuticals Inc	doxycycline hyclate	0440-1481	FD&C BLUE NO. 2
Liberty Pharmaceuticals Inc	doxycycline hyclate	0440-1481	FD&C RED NO. 40
Liberty Pharmaceuticals Inc	doxycycline hyclate	0440-1481	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in DOXYCYCLATE HYCLATE?

# Of NDCs	Excipient
2	ALCOHOL
2	BUTYL ALCOHOL
2	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
2	FD&C BLUE NO. 1
2	FD&C BLUE NO. 2
2	FD&C RED NO. 40

Doxycycline Hyclate Excipient Strategy and Commercial Opportunities

Last updated: November 8, 2026

Doxycycline hyclate is a mature, low-cost tetracycline with broad generic availability and limited active-ingredient patent protection. Commercial value has shifted from the molecule to dosage-form engineering, differentiated release profiles, pediatric delivery, adherence, dermatology positioning, and manufacturing efficiency. The strongest opportunities are modified-release oral products, alcohol- and sugar-conscious liquids, low-pill-burden regimens, and formulations that reduce food, mineral, and gastrointestinal-use constraints.

What is the commercial position of doxycycline hyclate?

Doxycycline hyclate is the hydrochloride salt of doxycycline. It is used in bacterial infections, acne, rosacea, malaria prophylaxis, sexually transmitted infections, respiratory infections, tick-borne disease, and selected inflammatory dermatology indications.

The product has an established FDA regulatory pathway, extensive clinical history, and multiple generic dosage forms. The main commercial constraint is price competition. The main commercial opportunity is differentiation.

Attribute	Commercial assessment
Active ingredient	Doxycycline hyclate
Therapeutic class	Tetracycline antibiotic
Primary oral strengths	20 mg, 40 mg, 50 mg, 75 mg, 100 mg, 150 mg
Common dosage forms	Capsules, tablets, delayed-release tablets, oral suspension, injectable products
FDA status	Approved drug with multiple abbreviated new drug applications
Core molecule exclusivity	Expired
Generic competition	Extensive
Main differentiation routes	Modified release, taste masking, liquid delivery, tolerability, packaging, supply reliability
Highest-value branded segments	Rosacea, acne, delayed-release and low-dose anti-inflammatory products
Key formulation risks	Moisture, light, acid-base conditions, metal-ion interactions, gastrointestinal irritation

The original Vibramycin products established doxycycline hyclate as an oral and parenteral antibiotic. Later products, including Oracea, Doryx and Acticlate, used dosage-form, strength, or release-profile differentiation rather than new chemical-entity protection.

What excipient strategy is appropriate for doxycycline hyclate?

The preferred excipient strategy depends on whether the product is an immediate-release capsule, conventional tablet, delayed-release product, liquid, or low-dose anti-inflammatory formulation.

Immediate-release capsules and tablets

Immediate-release products generally prioritize low manufacturing cost, rapid dissolution, chemical stability, and robust content uniformity. Typical excipient classes include:

Formulation function	Suitable excipient classes	Commercial purpose
Dilution and dose uniformity	Microcrystalline cellulose, lactose, starch, dibasic calcium phosphate where compatible	Controls fill weight and blend uniformity
Disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid tablet breakup
Lubrication	Magnesium stearate, sodium stearyl fumarate	Enables high-speed compression
Granulation	Povidone, hypromellose, pregelatinized starch	Improves flow and compactability
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide	Improves swallowability and protection
Capsule shell	Gelatin or hypromellose	Supports standard capsule manufacture

Doxycycline hyclate is relatively water soluble compared with several other tetracyclines. Excessive disintegrant loading or highly porous tablets can produce rapid local dissolution and increase the risk of esophageal exposure if the product is taken with insufficient water. The formulation should therefore balance rapid systemic release with tablet integrity and acceptable transit behavior.

Calcium-containing excipients require careful evaluation. Doxycycline forms poorly absorbed complexes with calcium, magnesium, aluminum, iron, and other polyvalent cations when they are present in the gastrointestinal tract. The risk is greatest with concomitant antacids, mineral supplements, and iron products. This pharmacokinetic issue does not prohibit every calcium-containing excipient, but it requires a justified formulation design, extractable assessment, dissolution testing, and clinical or bioequivalence support where exposure could be affected.

Moisture and light protection

Doxycycline products require packaging and process controls against moisture and light. Practical approaches include:

• Low-moisture excipient grades.
• Controlled-humidity blending and compression.
• High-barrier blister films.
• Aluminum-aluminum blister packaging for premium stability positioning.
• High-density polyethylene bottles with desiccant.
• Opaque film coating and light-resistant containers.
• Tight control of residual water in granules and coatings.

Doxycycline can undergo degradation and epimerization under adverse environmental conditions. Stability programs should monitor assay, related substances, dissolution, water content, color change, and degradation products under ICH long-term and accelerated conditions. Photostability testing is particularly relevant for clear or translucent packaging. [1,2]

pH and chemical compatibility

Formulators should avoid unnecessary alkaline microenvironments and should evaluate the pH of any aqueous phase used during granulation or coating. Buffer systems can improve liquid stability but may also accelerate degradation if their pH is poorly selected.

For tablets and capsules, excipient compatibility studies should include:

• Binary mixtures with major excipients.
• Accelerated temperature and humidity exposure.
• Differential scanning calorimetry or equivalent solid-state analysis.
• Chromatographic impurity profiling.
• Dissolution after storage.
• Evaluation of capsule-shell moisture transfer.

The commercial objective is a formulation that does not require an expensive excipient system unless the added materials create a measurable benefit in stability, release, tolerability, or regulatory differentiation.

What formulation technologies protect doxycycline products?

The strongest formulation opportunities involve release control and dosing convenience rather than conventional immediate-release products.

Delayed-release and dual-pulse systems

Doryx and related products demonstrated the commercial value of delayed-release doxycycline. A delayed-release design can use enteric polymers, multiparticulates, coated pellets, beads, or compressed units with functional coatings. The release profile can be engineered to reduce exposure in the upper gastrointestinal tract or to separate drug release into more than one phase.

Relevant excipient technologies include:

• Methacrylic acid copolymers.
• Hypromellose phthalate.
• Hypromellose acetate succinate.
• Ethylcellulose for sustained-release barriers.
• Plasticizers such as triethyl citrate or polyethylene glycol.
• Seal coats based on hypromellose or polyvinyl alcohol.
• Multiparticulate pellet systems.

The commercial barrier is not simply achieving delayed dissolution. The applicant must reproduce the reference product’s release profile, establish bioequivalence, control coating uniformity, and demonstrate stability across scale-up. Functional coating variability can materially affect exposure.

Low-dose 40 mg products

Oracea established a low-dose, modified-release doxycycline product for rosacea. Its commercial proposition is anti-inflammatory activity without the conventional antibiotic-dose positioning. A comparable product must address:

• Dose uniformity at low drug loading.
• Modified-release behavior.
• Food-effect characteristics.
• Clinical positioning in inflammatory dermatology.
• Potential impact on antimicrobial resistance messaging.
• Orange Book-listed formulation or method-of-use patents, where applicable.

The 40 mg segment has greater brand-value potential than standard 100 mg generic antibiotics because prescribers may prioritize chronic-use tolerability, disease-specific labeling, and patient adherence.

Taste-masked liquid and pediatric formulations

Liquid doxycycline products can address patients who cannot swallow capsules or tablets, including pediatric and geriatric populations. Commercial value depends on acceptable taste, reconstitution stability, dosing accuracy, and low microbial risk.

Suitable technologies include:

• Ion-exchange resin complexes.
• Polymer-coated drug particles.
• Lipid or wax dispersions.
• Suspensions with structured vehicles.
• Flavor systems combined with sweeteners and viscosity modifiers.
• Unit-dose oral syringes.

A liquid formulation should avoid excessive sugar where pediatric dental risk or diabetes-related prescribing concerns are relevant. Sugar-free systems using sorbitol, glycerol, sucralose, acesulfame potassium, or other approved sweeteners may support differentiation, but polyol levels must be controlled because gastrointestinal tolerance can limit acceptability.

What excipients are most attractive for commercial development?

The most commercially useful excipient systems are those that solve a specific product problem.

Commercial problem	Excipient or technology response	Opportunity
Bitter taste	Resin complex, polymer coating, flavor-masking system	Pediatric and adherence products
Esophageal irritation	Capsule lubrication, optimized disintegration, patient-use design	Consumer tolerability
Moisture sensitivity	Barrier coating, high-barrier blister, desiccant packaging	Longer shelf life and global distribution
Mineral interaction concerns	Calcium- and iron-free excipient platform	Cleaner interaction profile
Chronic-dose adherence	40 mg modified-release capsule or tablet	Dermatology
Swallowing difficulty	Oral suspension or sprinkle-compatible multiparticulates	Pediatric and elderly markets
High generic price pressure	Direct-compression platform, fewer process steps	Cost leadership
Supply volatility	Dual-source excipients and robust process design	Contract manufacturing and government supply

A calcium-free, low-moisture direct-compression platform may provide a practical base for immediate-release generics. A multiparticulate or coated-pellet platform is more suitable for premium products but requires higher development and manufacturing investment.

What patents protect doxycycline hyclate products?

The doxycycline hyclate active ingredient is not the principal source of current exclusivity. Patent value is concentrated in specific formulations, dosage strengths, release profiles, manufacturing processes, and labeled uses.

Patent categories

Patent category	Typical protected subject matter	Commercial relevance
Composition of matter	Doxycycline or salt form	Largely expired for conventional products
Formulation	Excipients, particle structure, coating system	Can delay generic substitution
Modified release	Delayed, sustained, or dual-pulse release	Important for Doryx- and Oracea-type products
Method of use	Rosacea, acne, inflammatory conditions, infection regimens	Supports labeled-use protection
Manufacturing	Pellet coating, granulation, impurity control, scale-up	Creates freedom-to-operate and supply barriers
Packaging	Moisture, light, or child-resistant systems	Usually secondary protection

The FDA Orange Book lists patents and regulatory exclusivities for approved products, but listed patents do not establish validity or enforceability. Generic applicants may file Paragraph IV certifications alleging that a listed patent is invalid, unenforceable, or not infringed. [3]

For doxycycline, a competitive assessment should distinguish:

1. Conventional immediate-release hyclate products with broad generic competition.
2. Low-dose modified-release products with narrower competition.
3. Delayed-release products with formulation-specific barriers.
4. Liquid products where formulation know-how and palatability may matter more than patents.
5. Injectable products where sterile manufacturing is the principal barrier.

Paragraph IV and litigation exposure

Paragraph IV risk is highest when a generic applicant targets a product with active formulation or method-of-use listings. The relevant legal events include:

• ANDA filing with a Paragraph IV certification.
• Notice letter to the patent holder.
• District-court filing within 45 days.
• Potential 30-month FDA approval stay.
• Settlement, license, authorized-generic arrangement, or litigation judgment.
• Final FDA approval after patent or exclusivity resolution.

A conventional doxycycline hyclate capsule generally has lower patent risk than a branded delayed-release or low-dose product. The litigation question must be evaluated product by product because the same active ingredient can carry materially different patent exposure across NDAs.

When does doxycycline hyclate lose exclusivity?

Conventional doxycycline hyclate products lost basic chemical exclusivity decades ago. FDA-approved generic entry is therefore available for multiple immediate-release presentations, subject to product-specific regulatory requirements.

The remaining exclusivity questions concern branded presentations:

Product type	Primary exclusivity issue
Immediate-release capsule	Generic substitution and ANDA competition
Conventional tablet	Formulation-specific patents, if listed
Oracea-type 40 mg product	Modified-release formulation and method-of-use patents
Doryx-type delayed-release product	Release technology and formulation patents
Pediatric liquid	Formulation, taste masking, stability, and labeling
Injectable product	Sterile manufacturing, container closure, and supply capacity

The FDA Orange Book should be reviewed for the current patent and exclusivity status of each reference-listed drug. [3] Patent expiration dates can differ from one dosage form or NDA to another, and pediatric exclusivity or patent-term adjustments can alter the effective generic-entry date.

What FDA regulatory pathway applies to new doxycycline products?

Immediate-release generic capsules and tablets generally use the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. Modified-release, low-dose, liquid, or materially different dosage forms may require additional comparative pharmacokinetic, dissolution, food-effect, or clinical data.

Key regulatory requirements include:

• Pharmaceutical equivalence.
• Bioequivalence to the reference listed drug.
• Comparative dissolution across media and pH conditions.
• Impurity and degradation-product control.
• Stability under ICH conditions.
• Container-closure qualification.
• Microbiological controls for liquids.
• Taste and redispersibility testing for suspensions.
• In-use stability after reconstitution or opening.

A 505(b)(2) application can be commercially useful when the product differs from an approved reference in formulation, route, strength, or dosing regimen and cannot be efficiently supported through an ANDA. The pathway may permit reliance on FDA findings for doxycycline while supporting differentiated clinical or pharmaceutical characteristics.

Which companies compete in doxycycline hyclate?

Competition spans originator, branded-generic, generic, specialty-pharmaceutical, and contract-manufacturing companies. Historical and current market participants have included Pfizer through Vibramycin legacy products, Galderma through Oracea, Mayne Pharma through Doryx products, and large generic manufacturers such as Teva, Viatris, Sandoz, Lupin, Sun Pharma, and Amneal, depending on product and market.

The competitive structure is fragmented:

• Standard 50 mg and 100 mg products compete mainly on price and supply reliability.
• 40 mg modified-release products compete on formulation, labeling, and dermatology relationships.
• Delayed-release products compete on reduced dosing frequency, tolerability, and physician familiarity.
• Liquids compete on palatability, stability, and pharmacy convenience.
• Hospital products compete on sterile capacity, shortage management, and procurement contracts.

What commercial opportunities exist for doxycycline hyclate?

Dermatology and chronic inflammatory use

The strongest branded opportunity is chronic dermatology, particularly rosacea and acne. A low-dose or modified-release product can command higher pricing than a conventional antibiotic if it provides disease-specific labeling, acceptable long-term tolerability, and a differentiated release profile.

Pediatric and geriatric delivery

Taste-masked suspensions, dispersible tablets, and multiparticulate products can address patients who cannot swallow standard capsules. Unit-dose packaging and oral syringes can improve administration accuracy and support institutional use.

Global access and supply resilience

Doxycycline is included in public-health and infectious-disease treatment frameworks. Manufacturers can compete through:

• Multiple API suppliers.
• Regional fill-finish capacity.
• High-barrier packaging.
• Reduced process complexity.
• Robust shelf life in hot and humid climates.
• Contract manufacturing for government and hospital tenders.

Combination and adherence products

Potential commercial concepts include blistered doxycycline with administration instructions, mineral-interaction warnings, or coordinated treatment packs. Combination products require careful regulatory analysis and may create new labeling and patent considerations.

Veterinary and specialty markets

Doxycycline products are also used in veterinary medicine. Veterinary suspensions, flavored tablets, and species-specific dosing formats can generate separate commercial opportunities, although they require distinct regulatory submissions and labeling.

How strong is the doxycycline hyclate patent estate?

The patent estate is weak for the conventional active ingredient and stronger for selected dosage forms. Its practical strength depends on claim breadth, remaining term, Orange Book listing, prior-art exposure, and the ease with which a generic can design around the formulation.

Product architecture	Patent strength	Generic-entry risk
Conventional immediate-release capsule	Low	High
Conventional 100 mg tablet	Low to moderate	High
Delayed-release multiparticulate	Moderate to high	Moderate
40 mg anti-inflammatory modified release	Moderate to high	Moderate
Sugar-free taste-masked suspension	Moderate	Moderate
Injectable hyclate product	Low patent strength, high manufacturing barrier	Moderate

Manufacturing know-how can remain commercially relevant after patent expiration. Coating uniformity, impurity control, taste masking, and scale-up may create practical barriers without excluding legally compliant competitors.

What generic launch scenarios exist?

A new entrant has four realistic launch strategies:

1. Low-cost immediate-release capsule or tablet.
2. Premium delayed-release product using a design-around formulation.
3. Pediatric or geriatric liquid with improved palatability.
4. Dermatology-focused low-dose product supported by a 505(b)(2) strategy or an ANDA where the reference permits it.

The first strategy has the lowest technical risk and the highest price pressure. The second and third strategies require more development but offer better margin potential. The fourth strategy has the greatest regulatory and patent complexity but can access a more defensible commercial segment.

Key Takeaways

• Doxycycline hyclate’s chemical exclusivity is expired; commercial protection comes from dosage form, release profile, labeling, manufacturing, and supply execution.
• Immediate-release products should use a low-cost, low-moisture excipient platform with strong dissolution and content-uniformity performance.
• Calcium, iron, magnesium, and aluminum interactions require careful formulation and labeling analysis.
• Modified-release 40 mg products and delayed-release products offer the strongest branded commercial opportunities.
• Taste-masked, sugar-free liquids can address pediatric, geriatric, and swallowing-impaired populations.
• High-barrier packaging and moisture control are central to shelf-life and global distribution.
• Orange Book review is essential for product-specific patent, exclusivity, and Paragraph IV analysis.
• The conventional generic market is highly price competitive; differentiated formulation platforms provide the more attractive margins.
• Manufacturing know-how, coating control, palatability, and supply reliability can create meaningful barriers even where patent protection is limited.

FAQs

Is doxycycline hyclate the same as doxycycline monohydrate?

No. Both are doxycycline salts, but their physical properties, excipient compatibility, dissolution behavior, and approved-product references can differ. A formulation cannot assume automatic substitutability without meeting applicable regulatory requirements.

Which excipients should be avoided in doxycycline hyclate products?

Formulators should scrutinize polyvalent cations, alkaline microenvironments, high-moisture systems, and excipients that accelerate degradation or compromise dissolution. Calcium- or iron-containing materials require particular compatibility and exposure analysis.

Can doxycycline hyclate be formulated as a once-daily product?

Yes. Once-daily products can use a higher strength, delayed release, modified release, or a product-specific dosing regimen. The formulation must demonstrate appropriate exposure, release, tolerability, and bioequivalence or clinical performance.

Is a doxycycline hyclate liquid commercially attractive?

Yes, where it improves taste, dosing flexibility, pediatric administration, or swallowing convenience. The principal development risks are palatability, sedimentation, reconstitution stability, microbial control, and dose uniformity.

Is a new doxycycline hyclate product likely to receive market exclusivity?

A conventional generic is unlikely to receive meaningful new exclusivity solely from using doxycycline hyclate. A novel formulation, new indication, clinical investigation, or 505(b)(2) product may qualify for limited regulatory exclusivity or obtain patent protection directed to the differentiated product.

References

1. U.S. Food and Drug Administration. (2018). Q1A(R2) stability testing of new drug substances and products. FDA.

2. U.S. Pharmacopeia. (2024). Doxycycline hyclate monograph. United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products and product-specific guidances for generic drug development. FDA.

5. U.S. Food and Drug Administration. (2023). Doxycycline prescribing information and approved product labeling. FDA.